Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776815 | 0.92 | MET (0.42) | METHDAC1TP53MEN1KMT2A | |
| SCHEMBL23297312 | 0.92 | MET (0.42) | METHDAC1TP53MEN1KMT2A | |
| SCHEMBL29776817 | 0.92 | MET (0.42) | METHDAC1TP53MEN1KMT2A | |
| SCHEMBL26626311 | 0.89 | TP53 (0.44) | METHDAC1TP53POLBMEN1 | |
| SCHEMBL26626478 | 0.88 | MET (0.47) | METHDAC1TP53PDE4APDE4B | |
| SCHEMBL26626975 | 0.86 | MEN1 (0.45) | METHDAC1TP53PDE4APDE4B | |
| SCHEMBL26626340 | 0.86 | TP53 (0.48) | METTP53PDE4APDE4BPDE4C | |
| SCHEMBL26626995 | 0.85 | MET (0.41) | METHDAC1TP53PDE4APDE4B | |
| SCHEMBL26529747 | 0.85 | MET (0.39) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26527994 | 0.85 | MET (0.40) | METTP53PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MET 4319/4885HDAC1 444/4885TP53 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.